Business Description
ISIN : US74366E1029
Total Employee Number:
141Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 84.92 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 128.55 | |||||
Beneish M-Score | -3.02 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.1 | |||||
3-Year EBITDA Growth Rate | 2.5 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year Book Growth Rate | 31 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.23 | |||||
9-Day RSI | 39.95 | |||||
14-Day RSI | 48.02 | |||||
3-1 Month Momentum % | 36.28 | |||||
6-1 Month Momentum % | 48.61 | |||||
12-1 Month Momentum % | 135.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.71 | |||||
Quick Ratio | 21.71 | |||||
Cash Ratio | 21.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 20.69 | |||||
Net Margin % | 29.4 | |||||
EBITDA Margin % | 21.24 | |||||
FCF Margin % | 46.31 | |||||
OCF Margin % | 46.53 | |||||
ROE % | 12.1 | |||||
ROA % | 11.29 | |||||
ROIC % | 46.56 | |||||
3-Year ROIIC % | -26.02 | |||||
ROC (Joel Greenblatt) % | 500.96 | |||||
ROCE % | 8.4 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 140.13 | |||||
Forward PE Ratio | 31.86 | |||||
PE Ratio without NRI | 140.13 | |||||
Price-to-Owner-Earnings | 121.8 | |||||
PS Ratio | 36.12 | |||||
PB Ratio | 11.09 | |||||
Price-to-Tangible-Book | 11.09 | |||||
Price-to-Free-Cash-Flow | 81.36 | |||||
Price-to-Operating-Cash-Flow | 80.9 | |||||
EV-to-EBIT | 146.82 | |||||
EV-to-EBITDA | 143.05 | |||||
EV-to-Revenue | 30.38 | |||||
EV-to-Forward-Revenue | 16.2 | |||||
EV-to-FCF | 65.6 | |||||
Price-to-GF-Value | 1.57 | |||||
Price-to-Projected-FCF | 13.33 | |||||
Price-to-Graham-Number | 8.31 | |||||
| Price-to-Net-Current-Asset-Value | 12.23 | |||||
| Price-to-Net-Cash | 12.64 | |||||
Earnings Yield (Greenblatt) % | 0.68 | |||||
FCF Yield % | 1.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTGX
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Protagonist Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 281.992 | ||
| EPS (TTM) ($) | 1.03 | ||
| Beta | 0.6259 | ||
| 3-Year Sharpe Ratio | 1.67 | ||
| 3-Year Sortino Ratio | 3.95 | ||
| Volatility % | 34.02 | ||
| 14-Day RSI | 48.02 | ||
| 14-Day ATR ($) | 5.770274 | ||
| 20-Day SMA ($) | 149.052 | ||
| 12-1 Month Momentum % | 135.36 | ||
| 52-Week Range ($) | 54.5 - 160.81 | ||
| Shares Outstanding (Mil) | 64.71 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protagonist Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protagonist Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 180 days | ||
| Annual report for 2026 | 2027-02-25 | In 179 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 68 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 135.81 (+2.10%) | ||
| General meeting for 2026 | 2026-06-17 10:00 | 110.64 (-2.66%) | ||
| Guidance call for 2026 | 2026-06-10 09:20 | 105.87 (+6.12%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 93.23 (-0.65%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 99.52 (+1.55%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 11:30 | 96.48 (-0.37%) | ||
| Citizens Life Sciences Conference | 2026-03-11 13:05 | 97.05 (+1.07%) |
Protagonist Therapeutics Inc Frequently Asked Questions
Guru Commentaries on NAS:PTGX
Protagonist Therapeutics is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock.
Protagonist Therapeutics is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock.
Protagonist Therapeutics is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock.
Press Release
Articles on Protagonist Therapeutics Inc
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
